Exenatide (Byetta): How the Gila Monster GLP-1 Works

What is exenatide?

Exenatide is a peptide, a short chain of 39 amino acids, made in a lab to match a molecule from a lizard. Its FDA label calls it a synthetic peptide, first spotted in Heloderma suspectum, the Gila monster. It weighs about 4,187 daltons, roughly the size of other GLP-1 drugs.

It belongs to the drug group called GLP-1 receptor agonists. A receptor is a lock on the outside of a cell, and an agonist is a key that turns it. Exenatide turns the GLP-1 lock, the one your own gut hormone GLP-1 uses after a meal. Lab tests show it latching onto the human GLP-1 receptor and activating it.

The odd part is how different it looks. Its chain matches human GLP-1 at only about 53% of its structure, yet it still fits the human lock. Like nearly every peptide drug, it was a shot rather than a pill, because the gut breaks peptides down. That gut problem is the reason vial math tools such as our peptide reconstitution calculator exist at all.

Sources: Byetta label (AstraZeneca, DailyMed); Furman, Toxicon, 2012; Liu, review in Frontiers in Endocrinology, 2024

Why does exenatide last longer than GLP-1?

Exenatide lasts longer than your own GLP-1 because the enzyme that switches GLP-1 off cannot cut it. That enzyme is DPP-4, short for dipeptidyl peptidase 4. It works like a ticket punch with one strict rule.

The rule. DPP-4 snips the first two building blocks off a peptide, but only when the second block is alanine or proline. Hormones in this family need their front end to work, so the snip turns them off. Human GLP-1 starts with histidine, then alanine. It fits the rule, so it gets clipped fast.

The dodge. Exenatide starts with histidine, then glycine. Glycine is not on the list, so DPP-4 passes it by. Reviews credit that one glycine for its resistance. The kidneys filter exenatide out instead, and enzymes break it down after that.

Because the kidneys do the clearing, kidney health matters. In people on dialysis, exposure to exenatide rose to about 3.4 times normal. The Byetta label says it is not advised in severe kidney disease.

Later, extended-release forms were made to let exenatide out slowly over a longer time. Newer GLP-1 drugs beat the DPP-4 problem in other ways, as the Ozempic section below explains.

Sources: Mentlein and colleagues, European Journal of Biochemistry, 1993; Egan and colleagues, American Journal of Physiology, 2003; Liu, review in Frontiers in Endocrinology, 2024; Byetta label (AstraZeneca, DailyMed); Bydureon BCise label (AstraZeneca, FDA, May 2025)

Where did exenatide come from?

Exenatide came from a hunt through lizard venom in a New York lab. In 1992, John Eng, a doctor and researcher working at the Bronx VA hospital, used a test that picks out peptides starting with histidine. In the venom of the Gila monster, a large lizard of the US Southwest, it found a 39-block peptide. His team named it exendin-4.

It had a near twin. Exendin-3 comes from a related lizard, Heloderma horridum. It differs from exendin-4 at only two spots, positions 2 and 3. Position 2 is where exendin-4 carries the glycine that later mattered so much. That small change also made the two peptides act differently on pancreas cells.

Eng then made a bold guess. If a lizard peptide had its own receptor on mammal pancreas cells, mammals had to make a matching hormone of their own. Later in 1992 his group found it. In guinea pig pancreas cells, the short active form of GLP-1 behaved like exendin-4 in every test they ran. By 1993, rat cell studies showed exendin-4 turning on the GLP-1 receptor strongly. It also raised insulin release.

From lab to drug. A 2012 review says exendin-4's much greater stability is what led to testing it as a diabetes drug. The VA says Eng licensed the discovery to an outside drug company. A company called Amylin turned it into a drug with Eli Lilly. Later, AstraZeneca took over the brands. Its 2014 release lists Byetta and Bydureon in that deal. It also lists Symlin (pramlintide), a copy of the hormone amylin. Amylin copies have their own episode: our animated look at cagrilintide.

Venom, not saliva. Some headlines say Gila monster spit. The 1992 papers say venom, and so does this page.

Sources: Eng and colleagues, Journal of Biological Chemistry, April 1992; Eng, Mount Sinai Journal of Medicine, March 1992; Raufman and colleagues, Journal of Biological Chemistry, October 1992; Goke and colleagues, Journal of Biological Chemistry, 1993; Furman, Toxicon, 2012; US Department of Veterans Affairs research summary; AstraZeneca news release, 3 February 2014; FDA review of exenatide in children, April 2025

What does exenatide do in the body?

Exenatide does three main things, and the Byetta label names all of them.

More insulin, but only when sugar is high. It makes the beta cells of the pancreas release insulin mainly when blood sugar is raised. As sugar falls back toward normal, that extra release fades. Think of a thermostat that only runs the cooling when the room is too hot.

Less glucagon. Glucagon signals the liver to release stored sugar. Exenatide holds it back when sugar runs high. The label adds that it does not block the normal glucagon response when sugar drops too low.

A slower stomach. It slows how fast food leaves the stomach, so sugar from a meal reaches the blood more slowly. In animal and human studies it also cut how much food was eaten.

Inside the cell, the label says, the insulin effect runs through cyclic AMP and other signals. Because insulin only rises with high sugar, the metformin add-on trial saw no more low blood sugar than placebo. The risk grew when exenatide was combined with sulfonylureas or insulin, which the next sections cover.

Sources: Byetta label (AstraZeneca, DailyMed); Bydureon BCise label (AstraZeneca, FDA, May 2025)

Byetta vs Bydureon vs Bydureon BCise: what is the difference?

All three hold the same exenatide molecule. They differ in how long each lasts and in what the FDA approved them for. Byetta is the short-acting original. Bydureon and Bydureon BCise are extended-release forms that let exenatide seep out slowly over weeks.

How the slow forms work. The Bydureon BCise label says the drug sits inside microspheres. These are tiny beads of a material the body breaks down, held in oil. As the beads soak up water and wear away, they let the drug out. After the last use, levels take about 10 weeks to fall below what tests can measure.

One shared rule. The Byetta and BCise labels both say not to combine them with another product that contains exenatide, since they hold the same drug.

One that never made it. ITCA 650 was another exenatide product, a drug built into a small device. The FDA turned it down in August 2024. It ruled that the maker had not shown it was safe for its planned use.

Sources: Byetta label (AstraZeneca, DailyMed); Bydureon BCise label (AstraZeneca, FDA, May 2025); FDA review of exenatide in children, April 2025; Drugs@FDA, Bydureon (NDA 022200); Federal Register, ITCA 650 decision, August 2024

What did the exenatide trials find?

In the trials behind Byetta, exenatide lowered A1C, a long-run blood sugar score, more than placebo did. The label pools three 30-week trials with 1,446 people. Their type 2 diabetes was not under control on metformin, a sulfonylurea or both. Adding Byetta cut A1C by roughly half a point to one point more than adding placebo.

Two of those trials were published on their own. One added exenatide to metformin in 336 people at 82 US sites. A1C fell with no weight gain and no rise in low blood sugar. The other added it to a sulfonylurea in 377 people at 101 US sites. A1C fell, and nobody had severe low blood sugar.

The heart trial. EXSCEL was set up to test heart safety first and heart benefit second. It compared extended-release exenatide with placebo in 14,752 people with type 2 diabetes. About three in four already had heart disease. Over a median of 3.2 years, 11.4% of the exenatide group had a major heart event, against 12.2% of the placebo group. A major event meant a heart death, heart attack or stroke.

That result had two parts. Exenatide met the safety goal: it did not raise heart risk. But the gap was too small to prove it protected the heart. The groups showed no clear difference in pancreatitis, pancreatic cancer or medullary thyroid cancer. Amylin Pharmaceuticals funded the trial.

Trial numbers are group averages. They do not predict how one person would respond.

Sources: Byetta label (AstraZeneca, DailyMed); DeFronzo and colleagues, Diabetes Care, 2005; Buse and colleagues, Diabetes Care, 2004; EXSCEL, New England Journal of Medicine, 2017

What are the side effects of exenatide?

The most common side effects of exenatide were in the gut. The Byetta label lists the side effects seen in at least 5% of people, and more often than on placebo. The top four were nausea, low blood sugar, vomiting and diarrhea. The rest were feeling jittery, dizziness, headache, indigestion, constipation and weakness. The label adds that nausea usually eases over time. On the Bydureon BCise label, the top two were a small lump under the skin where it went in, and nausea.

Warnings on the labels. Both labels warn of pancreatitis, a painful swelling of the pancreas, including fatal cases. They warn that low blood sugar is more likely alongside sulfonylureas or insulin. Some people who lost fluid through vomiting or diarrhea had sudden kidney injury, some needing dialysis. The labels also list severe gut problems and serious allergic reactions. Some people make antibodies that weaken the drug. A rare immune reaction can drop platelets, the cells that help stop bleeding, and that bleeding can be fatal. The list ends with gallbladder problems and the risk of inhaling stomach contents while under anesthesia.

The boxed warning, on BCise only. Extended-release exenatide caused thyroid C-cell tumors in rats at levels close to those in patients. Nobody knows if it does this in people. People who have had medullary thyroid cancer, or whose relatives have, should not use BCise, its label says. MEN 2, a rare inherited gland condition, also rules it out. The Byetta label has no boxed warning.

In April 2025, an FDA review of serious US reports in children found no new safety signals for exenatide. Only a person's own doctor can say how any of this applies to them.

Sources: Byetta label (AstraZeneca, DailyMed); Bydureon BCise label (AstraZeneca, FDA, May 2025); FDA review of exenatide in children, April 2025

Is exenatide still sold? Is Byetta discontinued?

No US exenatide product is sold today. We read the FDA's Orange Book data on 8 November 2026. All seven exenatide product lines were marked discontinued. That is two for Byetta, two for Bydureon, one for Bydureon BCise and two for the generic. Drugs@FDA shows the same.

Step one: sales stopped. The original Bydureon was permanently withdrawn from sale by March 2021. On 16 August 2024, AstraZeneca told the FDA it planned to stop marketing Byetta and Bydureon BCise for good. That came about 19 years after Byetta was first approved.

Step two: the approvals were withdrawn. A Federal Register notice on 4 August 2025 listed Byetta, Bydureon and Bydureon BCise. It said the FDA withdrew their approval as of 3 September 2025. The company had told the FDA the drugs were no longer sold, and it asked for the withdrawal itself. A 9 March 2026 notice named Bydureon and Bydureon BCise again, as of 8 April 2026. The notices let pharmacies dispense stock already on hand until it ran out or expired.

What it was not. This was not a safety recall. The notices use a rule, 21 CFR 314.150(c), for a company that asks the FDA to pull its own approval. They say the company can apply again later. The openFDA recall records showed no exenatide recall when we searched them. Neither the FDA nor AstraZeneca gave a business reason in any primary record we found.

Two loose ends. We found no notice that withdrew the generic's approval, and its label updates were approved in October 2026. Still, it is listed as discontinued. Also, one old Drugs@FDA record still reads Prescription. It is a 2009 Byetta filing for a new use, and the Orange Book still lists no exenatide product on sale. This page covers the US only. Our medical review policy sets out how we check status facts like these.

Sources: FDA Orange Book data files, October 2026 edition; Drugs@FDA, Byetta (NDA 021773); Drugs@FDA, Bydureon (NDA 022200); Drugs@FDA, Bydureon BCise (NDA 209210); Drugs@FDA, generic exenatide (ANDA 206697); FDA review of exenatide in children, April 2025; Federal Register, 4 August 2025 withdrawal notice; Federal Register, 9 March 2026 withdrawal notice; openFDA drug recall records, searched 8 November 2026

Did the Gila monster lead to Ozempic?

The Gila monster led to the first GLP-1 drug, not to Ozempic itself. Ozempic and Wegovy contain semaglutide, which is built from human GLP-1, not from venom. Its label says it shares 94% of its sequence with the human hormone, and yeast makes its peptide backbone.

Exenatide was the first approved drug to prove a point in people. Turning the GLP-1 lock could lower blood sugar, once the DPP-4 cutter was dodged. Later drugs dodge it their own way. Semaglutide has a swapped block at position 8 that resists DPP-4. It also has a fatty chain that grips albumin, a blood protein. Together these let it last about a week. Our oral semaglutide explainer shows how that same molecule gets into the blood from a tablet, and the shot form has its own semaglutide reconstitution calculator.

The lizard still left a mark on a newer drug. Tirzepatide, sold as Mounjaro and Zepbound, has a tail shaped like the end of exendin-4. That tail helps it grip the GLP-1 receptor. Our first animated explainer, on tirzepatide, follows that tail, and the tirzepatide reconstitution calculator handles its vial arithmetic.

The family keeps growing. Retatrutide, still in trials, adds the glucagon lock to GIP and GLP-1. Our retatrutide calculator maps out a weight timeline from the stats you enter. All of them act on the same GLP-1 lock that exenatide was the first drug to target.

Sources: Wegovy label (Novo Nordisk, DailyMed); Furman, Toxicon, 2012; Raufman and colleagues, Journal of Biological Chemistry, October 1992; EXSCEL, New England Journal of Medicine, 2017

What else do people ask about exenatide?

Sources: Byetta label (AstraZeneca, DailyMed); Bydureon BCise label (AstraZeneca, FDA, May 2025); FDA review of exenatide in children, April 2025; Eng and colleagues, Journal of Biological Chemistry, April 1992; Furman, Toxicon, 2012; Wegovy label (Novo Nordisk, DailyMed); FDA Orange Book data files, October 2026 edition; Federal Register, 4 August 2025 withdrawal notice; Drugs@FDA, generic exenatide (ANDA 206697); openFDA drug recall records, searched 8 November 2026; DeFronzo and colleagues, Diabetes Care, 2005; Buse and colleagues, Diabetes Care, 2004

What did we learn about exenatide?

Exenatide is a lizard's key copied in a lab. One glycine near its front lets it slip past DPP-4, so it works for hours where human GLP-1 lasts a couple of minutes. It became Byetta in 2005, then Bydureon and Bydureon BCise. It lowered A1C in trials and did not raise heart risk in EXSCEL. In the US, sales ended and the brand approvals were later withdrawn at the company's request.

Each Molecule Mechanics video animates one peptide drug: the molecule, its history and its trial record. No episode tells anyone what to take or where to find it. The narration is synthetic speech made with ElevenLabs software. The pictures are animated just for the series, and each video description names its sources. Earlier episodes covered tirzepatide, cagrilintide and oral semaglutide. Setmelanotide, sold as Imcivree, has a written page as well: our Imcivree article.

See a mistake here? Our corrections policy explains how to tell us and how we fix pages.

See all Molecule Mechanics videos on YouTube

Sources: Molecule Mechanics on YouTube